Waldencast buys back 193,816 RSUs from executive

Waldencast plc reported that Chief Growth Officer and director Hind Sebti disposed of 193,816 Restricted Stock Units, each representing one Class A ordinary share, in a disposition to the issuer at $2.00 per RSU.

Rhea-AI Filing Summary

Waldencast plc reported that Chief Growth Officer and director Hind Sebti disposed of 193,816 Restricted Stock Units, each representing one Class A ordinary share, in a disposition to the issuer at $2.00 per RSU. The RSUs were purchased by Waldencast in connection with the completion of the sale of its Obagi Medical dermatological skincare and aesthetics business on July 30, 2026, when Sebti transitioned to lead Obagi Medical. These RSUs came from an October 30, 2024 grant of 290,723 RSUs that had been scheduled to vest in three annual tranches, and following this transaction no RSUs from this grant remain reported for Sebti.

Insider Trade Summary

Disposition: 193,816 shares

Disposition 1 txn

Insider Sebti Hind

Role Chief Growth Officer

Type	Security	Shares	Price	Value
Disposition	Restricted Stock Units F1, F2, F3	193,816	$2.00	$388K

Holdings After Transaction: Restricted Stock Units — 0 contracts (Direct)

Footnotes (3)

1. F1. Each restricted stock unit ("RSU") represents a contingent right to receive one Class A ordinary share, or an equivalent value in cash at the plan administrator's election.
2. F2. Represents the Issuer's purchase of 193,816 outstanding RSUs held by the reporting person in connection with the completion of the Issuer's sale of its Obagi Medical dermatological skincare and aesthetics business on July 30, 2026. Effective on the date of completion of such sale, the reporting person transitioned from the Issuer to lead Obagi Medical.
3. F3. On October 30, 2024, the reporting person was granted 290,723 RSUs, which would have vested over a three-year period as follows: (i) 96,907 on October 1, 2025; (ii) 96,908 on October 1, 2026; and (iii) 96,908 on October 1, 2027.

Key Figures

RSUs disposed: 193,816 RSUs Price per RSU: $2.0000 RSUs following transaction: 0 +4 more

7 metrics

RSUs disposed 193,816 RSUs Restricted Stock Units purchased by Waldencast from Hind Sebti on July 30, 2026

Price per RSU $2.0000 Per-unit price for 193,816 RSUs disposed to Waldencast

RSUs following transaction 0 Derivative RSU holdings reported for Hind Sebti after issuer purchase

Original RSU grant 290,723 RSUs RSUs granted to Hind Sebti on October 30, 2024

First vesting tranche 96,907 RSUs Scheduled to vest on October 1, 2025 from the October 30, 2024 grant

Second vesting tranche 96,908 RSUs Scheduled to vest on October 1, 2026 from the October 30, 2024 grant

Third vesting tranche 96,908 RSUs Scheduled to vest on October 1, 2027 from the October 30, 2024 grant

Key Terms

Restricted Stock Units, contingent right, Class A ordinary share, disposition to issuer, +1 more

5 terms

Restricted Stock Units financial

"Each restricted stock unit ("RSU") represents a contingent right to receive one Class A"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

contingent right financial

"Each restricted stock unit ("RSU") represents a contingent right to receive one Class A"

Class A ordinary share financial

"right to receive one Class A ordinary share, or an equivalent value in cash at the plan"

A Class A ordinary share is a type of common stock a company issues that carries a specific set of rights—most often particular voting power, dividend terms, or transfer rules—distinct from other share classes. For investors it matters because those rights affect control over company decisions, how income is paid out, and how easy shares are to buy or sell; think of it like a tiered ticket that gives different access and influence at the same event.

disposition to issuer financial

"Transaction coded as a disposition to issuer representing the issuer's purchase of RSUs"

dermatological skincare and aesthetics business financial

"completion of the Issuer's sale of its Obagi Medical dermatological skincare and"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Waldencast (WALD) report for Hind Sebti?

Hind Sebti disposed of 193,816 Restricted Stock Units in a transaction where Waldencast purchased the RSUs. Each RSU represented one Class A ordinary share, and the disposition occurred in connection with the sale of the Obagi Medical business completed on July 30, 2026.

How many RSUs were involved in Hind Sebti’s Waldencast (WALD) transaction and at what price?

The transaction covered 193,816 RSUs at $2.00 per RSU, representing a disposition to Waldencast. Each RSU corresponded to one Class A ordinary share or equivalent cash value at the plan administrator’s election, and all 193,816 RSUs were purchased by the issuer.

How is the Waldencast (WALD) insider transaction linked to the Obagi Medical sale?

The disposition represents Waldencast’s purchase of 193,816 outstanding RSUs from Hind Sebti in connection with completing the sale of its Obagi Medical dermatological skincare and aesthetics business on July 30, 2026, when Sebti transitioned from Waldencast to lead Obagi Medical.

What were the original RSU grant terms for Hind Sebti at Waldencast (WALD)?

On October 30, 2024, Hind Sebti was granted 290,723 RSUs, scheduled to vest over three years: 96,907 RSUs on October 1, 2025, 96,908 on October 1, 2026, and 96,908 on October 1, 2027, before the later issuer purchase of 193,816 RSUs.

What is Hind Sebti’s RSU position after the reported Waldencast (WALD) transaction?

Following Waldencast’s purchase of 193,816 RSUs from Hind Sebti, the filing reports 0 RSUs remaining from this derivative position. The transaction is coded as a disposition to the issuer, and no continuing derivative holdings are shown in this filing’s summary data.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/07/2026 - 04:11 PM Accepted by SEC EDGAR 08/07/2026 - 04:10 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sebti Hind

(Last) (First) (Middle)

C/O WALDENCAST PLC

MICHELIN HOUSE, 81 FULHAM ROAD

(Street)

LONDON SW3 6RD

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
Waldencast plc [ WALD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Growth Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	07/30/2026		D(2)			193,816	(3)	(3)	Class A Ordinary Shares	193,816	$2	0	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one Class A ordinary share, or an equivalent value in cash at the plan administrator's election.

2. Represents the Issuer's purchase of 193,816 outstanding RSUs held by the reporting person in connection with the completion of the Issuer's sale of its Obagi Medical dermatological skincare and aesthetics business on July 30, 2026. Effective on the date of completion of such sale, the reporting person transitioned from the Issuer to lead Obagi Medical.

3. On October 30, 2024, the reporting person was granted 290,723 RSUs, which would have vested over a three-year period as follows: (i) 96,907 on October 1, 2025; (ii) 96,908 on October 1, 2026; and (iii) 96,908 on October 1, 2027.

Remarks:

	/s/ Hind Sebti	08/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)